C
AbbVie Inc.
ABBV
$168.05
-$1.49-0.88%
C
Hold
4/18/2024Upgraded
AbbVie Inc. (ABBV) was upgraded to C+ from C on 4/18/2024 due to an increase in the volatility index, valuation index and dividend index.
AbbVie Inc. (ABBV) was upgraded to C+ from C on 4/18/2024 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
3/27/2024Downgrade
AbbVie Inc. (ABBV) was downgraded to C from C+ on 3/27/2024 due to a decline in the total return index.
AbbVie Inc. (ABBV) was downgraded to C from C+ on 3/27/2024 due to a decline in the total return index.
C
Hold
3/12/2024Upgraded
AbbVie Inc. (ABBV) was upgraded to C+ from C on 3/12/2024 due to a major increase in the total return index, volatility index and growth index. EBIT increased 83.95% from $2.47B to $4.55B, and total revenue increased 2.69% from $13.93B to $14.3B.
AbbVie Inc. (ABBV) was upgraded to C+ from C on 3/12/2024 due to a major increase in the total return index, volatility index and growth index. EBIT increased 83.95% from $2.47B to $4.55B, and total revenue increased 2.69% from $13.93B to $14.3B.
C
Hold
11/9/2023Downgrade
AbbVie Inc. (ABBV) was downgraded to C from C+ on 11/9/2023 due to a noticeable decline in the total return index and volatility index.
AbbVie Inc. (ABBV) was downgraded to C from C+ on 11/9/2023 due to a noticeable decline in the total return index and volatility index.
C
Hold
11/7/2023Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B on 11/7/2023 due to a significant decline in the growth index, valuation index and volatility index. EBIT declined 48.18% from $4.77B to $2.47B, and earnings per share declined from $1.1392 to $1.
AbbVie Inc. (ABBV) was downgraded to C+ from B on 11/7/2023 due to a significant decline in the growth index, valuation index and volatility index. EBIT declined 48.18% from $4.77B to $2.47B, and earnings per share declined from $1.1392 to $1.
B
Buy
9/19/2023Upgraded
AbbVie Inc. (ABBV) was upgraded to B from B- on 9/19/2023 due to an increase in the total return index, volatility index and solvency index.
AbbVie Inc. (ABBV) was upgraded to B from B- on 9/19/2023 due to an increase in the total return index, volatility index and solvency index.
B
Buy
8/8/2023Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C on 8/8/2023 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.1288 to $1.1392, net income increased 746.86% from $239M to $2.02B, and EBIT increased 56.87% from $3.04B to $4.77B.
AbbVie Inc. (ABBV) was upgraded to B- from C on 8/8/2023 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.1288 to $1.1392, net income increased 746.86% from $239M to $2.02B, and EBIT increased 56.87% from $3.04B to $4.77B.
C
Hold
7/28/2023Downgrade
AbbVie Inc. (ABBV) was downgraded to C from C+ on 7/28/2023 due to a noticeable decline in the total return index and volatility index.
AbbVie Inc. (ABBV) was downgraded to C from C+ on 7/28/2023 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/8/2023Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B on 5/8/2023 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.3847 to $0.1288, EBIT declined 55.74% from $6.87B to $3.04B, and operating cash flow declined 43.55% from $7.43B to $4.19B.
AbbVie Inc. (ABBV) was downgraded to C+ from B on 5/8/2023 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.3847 to $0.1288, EBIT declined 55.74% from $6.87B to $3.04B, and operating cash flow declined 43.55% from $7.43B to $4.19B.
B
Buy
1/30/2023Downgrade
AbbVie Inc. (ABBV) was downgraded to B from A- on 1/30/2023 due to a substantial decline in the total return index.
AbbVie Inc. (ABBV) was downgraded to B from A- on 1/30/2023 due to a substantial decline in the total return index.
A
Buy
1/23/2023Upgraded
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 1/23/2023 due to a noticeable increase in the total return index, valuation index and dividend index.
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 1/23/2023 due to a noticeable increase in the total return index, valuation index and dividend index.
B
Buy
12/28/2022Downgrade
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 12/28/2022 due to a decline in the total return index.
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 12/28/2022 due to a decline in the total return index.
A
Buy
12/13/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 12/13/2022 due to a large increase in the total return index and growth index.
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 12/13/2022 due to a large increase in the total return index and growth index.
B
Buy
12/2/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 12/2/2022 due to a major increase in the total return index and valuation index.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 12/2/2022 due to a major increase in the total return index and valuation index.
B
Buy
7/22/2022Downgrade
AbbVie Inc. (ABBV) was downgraded to B from B+ on 7/22/2022 due to a large decline in the total return index.
AbbVie Inc. (ABBV) was downgraded to B from B+ on 7/22/2022 due to a large decline in the total return index.
B
Buy
7/7/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 7/7/2022 due to an increase in the total return index.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 7/7/2022 due to an increase in the total return index.
B
Buy
6/3/2022Downgrade
AbbVie Inc. (ABBV) was downgraded to B from A- on 6/3/2022 due to a substantial decline in the total return index.
AbbVie Inc. (ABBV) was downgraded to B from A- on 6/3/2022 due to a substantial decline in the total return index.
A
Buy
5/27/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 5/27/2022 due to a noticeable increase in the total return index and valuation index.
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 5/27/2022 due to a noticeable increase in the total return index and valuation index.
B
Buy
5/6/2022Downgrade
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 5/6/2022 due to a decline in the growth index and volatility index. EBIT declined 10.25% from $5.59B to $5.02B, total revenue declined 9.06% from $14.89B to $13.54B, and operating cash flow declined 3.29% from $5.08B to $4.91B.
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 5/6/2022 due to a decline in the growth index and volatility index. EBIT declined 10.25% from $5.59B to $5.02B, total revenue declined 9.06% from $14.89B to $13.54B, and operating cash flow declined 3.29% from $5.08B to $4.91B.
A
Buy
4/27/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 4/27/2022 due to an increase in the total return index and volatility index.
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 4/27/2022 due to an increase in the total return index and volatility index.
B
Buy
3/25/2022Downgrade
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 3/25/2022 due to a decline in the total return index, valuation index and dividend index.
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 3/25/2022 due to a decline in the total return index, valuation index and dividend index.
A
Buy
3/7/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 3/7/2022 due to a noticeable increase in the total return index and volatility index.
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 3/7/2022 due to a noticeable increase in the total return index and volatility index.
B
Buy
2/23/2022Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 2/23/2022 due to a substantial increase in the growth index, total return index and valuation index. Earnings per share increased from $1.78 to $2.2611, EBIT increased 14.15% from $4.9B to $5.59B, and total revenue increased 3.79% from $14.34B to $14.89B.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 2/23/2022 due to a substantial increase in the growth index, total return index and valuation index. Earnings per share increased from $1.78 to $2.2611, EBIT increased 14.15% from $4.9B to $5.59B, and total revenue increased 3.79% from $14.34B to $14.89B.
B
Buy
11/26/2021Upgraded
AbbVie Inc. (ABBV) was upgraded to B from B- on 11/26/2021 due to an increase in the volatility index.
AbbVie Inc. (ABBV) was upgraded to B from B- on 11/26/2021 due to an increase in the volatility index.
B
Buy
11/4/2021Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 11/4/2021 due to a major increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.419 to $1.78, operating cash flow increased 62.27% from $4.89B to $7.94B, and EBIT increased 4.28% from $4.7B to $4.9B.
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 11/4/2021 due to a major increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.419 to $1.78, operating cash flow increased 62.27% from $4.89B to $7.94B, and EBIT increased 4.28% from $4.7B to $4.9B.
C
Hold
5/10/2021Upgraded
AbbVie Inc. (ABBV) was upgraded to C+ from C on 5/10/2021 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from $0.009 to $1.99, and operating cash flow increased 0.47% from $4.85B to $4.88B.
AbbVie Inc. (ABBV) was upgraded to C+ from C on 5/10/2021 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from $0.009 to $1.99, and operating cash flow increased 0.47% from $4.85B to $4.88B.
C
Hold
2/19/2021Downgrade
AbbVie Inc. (ABBV) was downgraded to C from B- on 2/19/2021 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.29 to $0.009, operating cash flow declined 16.74% from $5.83B to $4.85B, and debt to equity increased from 5.7 to 6.6.
AbbVie Inc. (ABBV) was downgraded to C from B- on 2/19/2021 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.29 to $0.009, operating cash flow declined 16.74% from $5.83B to $4.85B, and debt to equity increased from 5.7 to 6.6.
B
Buy
12/11/2020Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 12/11/2020 due to an increase in the total return index, volatility index and solvency index.
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 12/11/2020 due to an increase in the total return index, volatility index and solvency index.
C
Hold
11/12/2020Upgraded
AbbVie Inc. (ABBV) was upgraded to C+ from C on 11/12/2020 due to a significant increase in the growth index, volatility index and efficiency index. Net income increased 412.74% from -$738M to $2.31B, earnings per share increased from -$0.46 to $1.29, and operating cash flow increased 88.73% from $3.09B to $5.83B.
AbbVie Inc. (ABBV) was upgraded to C+ from C on 11/12/2020 due to a significant increase in the growth index, volatility index and efficiency index. Net income increased 412.74% from -$738M to $2.31B, earnings per share increased from -$0.46 to $1.29, and operating cash flow increased 88.73% from $3.09B to $5.83B.
C
Hold
11/9/2020Upgraded
AbbVie Inc. (ABBV) was upgraded to C from C- on 11/9/2020 due to an increase in the volatility index.
AbbVie Inc. (ABBV) was upgraded to C from C- on 11/9/2020 due to an increase in the volatility index.
C
Hold
10/23/2020Downgrade
AbbVie Inc. (ABBV) was downgraded to C- from C on 10/23/2020 due to a noticeable decline in the total return index, volatility index and solvency index.
AbbVie Inc. (ABBV) was downgraded to C- from C on 10/23/2020 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
8/5/2020Downgrade
AbbVie Inc. (ABBV) was downgraded to C from B- on 8/5/2020 due to a significant decline in the growth index and valuation index. Earnings per share declined from $2.0147 to -$0.46, and operating cash flow declined 19.03% from $3.82B to $3.09B.
AbbVie Inc. (ABBV) was downgraded to C from B- on 8/5/2020 due to a significant decline in the growth index and valuation index. Earnings per share declined from $2.0147 to -$0.46, and operating cash flow declined 19.03% from $3.82B to $3.09B.
B
Buy
6/29/2020Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 6/29/2020 due to an increase in the growth index and total return index. EBIT increased 17.74% from $3.08B to $3.62B, operating cash flow increased 16.49% from $3.28B to $3.82B, and earnings per share increased from $1.871 to $2.02.
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 6/29/2020 due to an increase in the growth index and total return index. EBIT increased 17.74% from $3.08B to $3.62B, operating cash flow increased 16.49% from $3.28B to $3.82B, and earnings per share increased from $1.871 to $2.02.
C
Hold
3/16/2020Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 3/16/2020 due to a decline in the total return index and solvency index.
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 3/16/2020 due to a decline in the total return index and solvency index.
B
Buy
2/21/2020Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C on 2/21/2020 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $1.26 to $1.871, and total revenue increased 2.65% from $8.48B to $8.7B.
AbbVie Inc. (ABBV) was upgraded to B- from C on 2/21/2020 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $1.26 to $1.871, and total revenue increased 2.65% from $8.48B to $8.7B.
C
Hold
11/5/2019Upgraded
AbbVie Inc. (ABBV) was upgraded to C from C- on 11/5/2019 due to an increase in the volatility index.
AbbVie Inc. (ABBV) was upgraded to C from C- on 11/5/2019 due to an increase in the volatility index.
C
Hold
8/7/2019Downgrade
AbbVie Inc. (ABBV) was downgraded to C- from C on 8/7/2019 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $1.6508 to $0.49, and operating cash flow declined 17.9% from $3.02B to $2.48B.
AbbVie Inc. (ABBV) was downgraded to C- from C on 8/7/2019 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $1.6508 to $0.49, and operating cash flow declined 17.9% from $3.02B to $2.48B.
C
Hold
6/25/2019Downgrade
AbbVie Inc. (ABBV) was downgraded to C from C+ on 6/25/2019 due to a noticeable decline in the volatility index, total return index and valuation index.
AbbVie Inc. (ABBV) was downgraded to C from C+ on 6/25/2019 due to a noticeable decline in the volatility index, total return index and valuation index.
C
Hold
3/4/2019Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 3/4/2019 due to a major decline in the growth index, volatility index and efficiency index. Earnings per share declined from $1.81 to -$1.2179, net income declined 166.47% from $2.75B to -$1.83B, and operating cash flow declined 25.02% from $4.52B to $3.39B.
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 3/4/2019 due to a major decline in the growth index, volatility index and efficiency index. Earnings per share declined from $1.81 to -$1.2179, net income declined 166.47% from $2.75B to -$1.83B, and operating cash flow declined 25.02% from $4.52B to $3.39B.
B
Buy
1/25/2019Downgrade
AbbVie Inc. (ABBV) was downgraded to B- from B on 1/25/2019 due to a decline in the volatility index and total return index.
AbbVie Inc. (ABBV) was downgraded to B- from B on 1/25/2019 due to a decline in the volatility index and total return index.
B
Buy
1/10/2019Upgraded
AbbVie Inc. (ABBV) was upgraded to B from B- on 1/10/2019 due to an increase in the total return index and valuation index.
AbbVie Inc. (ABBV) was upgraded to B from B- on 1/10/2019 due to an increase in the total return index and valuation index.
B
Buy
12/11/2018Downgrade
AbbVie Inc. (ABBV) was downgraded to B- from B on 12/11/2018 due to a significant decline in the total return index and volatility index.
AbbVie Inc. (ABBV) was downgraded to B- from B on 12/11/2018 due to a significant decline in the total return index and volatility index.
B
Buy
2/20/2018Downgrade
AbbVie Inc. (ABBV) was downgraded to B from B+ on 2/20/2018 due to a noticeable decline in the solvency index, valuation index and growth index. Earnings per share declined from $1.01 to $0.0321, debt to equity increased from 5.7 to 7.33, and operating cash flow declined 21% from $3.27B to $2.58B.
AbbVie Inc. (ABBV) was downgraded to B from B+ on 2/20/2018 due to a noticeable decline in the solvency index, valuation index and growth index. Earnings per share declined from $1.01 to $0.0321, debt to equity increased from 5.7 to 7.33, and operating cash flow declined 21% from $3.27B to $2.58B.
B
Buy
2/1/2018Downgrade
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 2/1/2018 due to a decline in the valuation index, volatility index and dividend index.
AbbVie Inc. (ABBV) was downgraded to B+ from A- on 2/1/2018 due to a decline in the valuation index, volatility index and dividend index.
A
Buy
11/16/2017Upgraded
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 11/16/2017 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.98 to 1.11, and debt to equity declined from 6.25 to 5.7.
AbbVie Inc. (ABBV) was upgraded to A- from B+ on 11/16/2017 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.98 to 1.11, and debt to equity declined from 6.25 to 5.7.
B
Buy
10/6/2017Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 10/6/2017 due to a major increase in the total return index, solvency index and volatility index. Debt to equity declined from 7.46 to 6.25.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 10/6/2017 due to a major increase in the total return index, solvency index and volatility index. Debt to equity declined from 7.46 to 6.25.
B
Buy
3/23/2017Upgraded
AbbVie Inc. (ABBV) was upgraded to B from B- on 3/23/2017 due to an increase in the total return index and volatility index.
AbbVie Inc. (ABBV) was upgraded to B from B- on 3/23/2017 due to an increase in the total return index and volatility index.
B
Buy
3/8/2017Downgrade
AbbVie Inc. (ABBV) was downgraded to B- from B on 3/8/2017 due to a decline in the volatility index, valuation index and dividend index.
AbbVie Inc. (ABBV) was downgraded to B- from B on 3/8/2017 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
2/21/2017Upgraded
AbbVie Inc. (ABBV) was upgraded to B from B- on 2/21/2017 due to an increase in the volatility index, total return index and dividend index.
AbbVie Inc. (ABBV) was upgraded to B from B- on 2/21/2017 due to an increase in the volatility index, total return index and dividend index.
B
Buy
2/6/2017Downgrade
AbbVie Inc. (ABBV) was downgraded to B- from B on 2/6/2017 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 24.19% from $1.92B to $1.45B, EBIT declined 2.96% from $2.57B to $2.5B, and earnings per share declined from $0.98 to $0.97.
AbbVie Inc. (ABBV) was downgraded to B- from B on 2/6/2017 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 24.19% from $1.92B to $1.45B, EBIT declined 2.96% from $2.57B to $2.5B, and earnings per share declined from $0.98 to $0.97.
B
Buy
8/5/2016Upgraded
AbbVie Inc. (ABBV) was upgraded to B from B- on 8/5/2016 due to a noticeable increase in the solvency index, growth index and total return index. Earnings per share increased from $0.83 to $0.98, the quick ratio increased from 1.25 to 1.41, and EBIT increased 8.39% from $2.37B to $2.57B.
AbbVie Inc. (ABBV) was upgraded to B from B- on 8/5/2016 due to a noticeable increase in the solvency index, growth index and total return index. Earnings per share increased from $0.83 to $0.98, the quick ratio increased from 1.25 to 1.41, and EBIT increased 8.39% from $2.37B to $2.57B.
B
Buy
3/14/2016Downgrade
AbbVie Inc. (ABBV) was downgraded to B- from B on 3/14/2016 due to a decline in the volatility index, total return index and valuation index.
AbbVie Inc. (ABBV) was downgraded to B- from B on 3/14/2016 due to a decline in the volatility index, total return index and valuation index.
B
Buy
2/19/2016Upgraded
AbbVie Inc. (ABBV) was upgraded to B from C+ on 2/19/2016 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.74 to $0.9091, EBIT increased 13.87% from $2.01B to $2.28B, and total revenue increased 7.67% from $5.94B to $6.4B.
AbbVie Inc. (ABBV) was upgraded to B from C+ on 2/19/2016 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.74 to $0.9091, EBIT increased 13.87% from $2.01B to $2.28B, and total revenue increased 7.67% from $5.94B to $6.4B.
C
Hold
1/12/2016Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 1/12/2016 due to a decline in the total return index, volatility index and valuation index.
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 1/12/2016 due to a decline in the total return index, volatility index and valuation index.
B
Buy
12/28/2015Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 12/28/2015 due to an increase in the valuation index, volatility index and dividend index.
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 12/28/2015 due to an increase in the valuation index, volatility index and dividend index.
C
Hold
11/10/2015Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 11/10/2015 due to a noticeable decline in the growth index, solvency index and volatility index. Debt to equity increased from 5.69 to 6.61, EBIT declined 12.1% from $2.28B to $2.01B, and earnings per share declined from $0.83 to $0.74.
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 11/10/2015 due to a noticeable decline in the growth index, solvency index and volatility index. Debt to equity increased from 5.69 to 6.61, EBIT declined 12.1% from $2.28B to $2.01B, and earnings per share declined from $0.83 to $0.74.
B
Buy
11/2/2015Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 11/2/2015 due to an increase in the volatility index and valuation index.
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 11/2/2015 due to an increase in the volatility index and valuation index.
C
Hold
10/13/2015Downgrade
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 10/13/2015 due to a major decline in the volatility index.
AbbVie Inc. (ABBV) was downgraded to C+ from B- on 10/13/2015 due to a major decline in the volatility index.
B
Buy
9/25/2015Upgraded
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 9/25/2015 due to a large increase in the solvency index, valuation index and growth index. Debt to equity declined from 11.13 to 5.69, earnings per share increased from $0.63 to $0.83, and EBIT increased 18.56% from $1.92B to $2.28B.
AbbVie Inc. (ABBV) was upgraded to B- from C+ on 9/25/2015 due to a large increase in the solvency index, valuation index and growth index. Debt to equity declined from 11.13 to 5.69, earnings per share increased from $0.63 to $0.83, and EBIT increased 18.56% from $1.92B to $2.28B.
C
Hold
6/19/2015Upgraded
AbbVie Inc. (ABBV) was upgraded to C+ from C on 6/19/2015 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 29.48% from $1.49B to $1.92B.
AbbVie Inc. (ABBV) was upgraded to C+ from C on 6/19/2015 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 29.48% from $1.49B to $1.92B.
C
Hold
2/20/2015Downgrade
AbbVie Inc. (ABBV) was downgraded to C from B on 2/20/2015 due to a significant decline in the valuation index, solvency index and growth index. Earnings per share declined from $0.31 to -$0.5128, debt to equity increased from 3.24 to 8.62, and operating cash flow declined 132.36% from $1.79B to -$578M.
AbbVie Inc. (ABBV) was downgraded to C from B on 2/20/2015 due to a significant decline in the valuation index, solvency index and growth index. Earnings per share declined from $0.31 to -$0.5128, debt to equity increased from 3.24 to 8.62, and operating cash flow declined 132.36% from $1.79B to -$578M.
B
Buy
10/29/2014Downgrade
AbbVie Inc. (ABBV) was downgraded to B from B+ on 10/29/2014 due to a decline in the total return index.
AbbVie Inc. (ABBV) was downgraded to B from B+ on 10/29/2014 due to a decline in the total return index.
B
Buy
10/7/2014Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 10/7/2014 due to an increase in the valuation index.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 10/7/2014 due to an increase in the valuation index.
B
Buy
9/22/2014Downgrade
AbbVie Inc. (ABBV) was downgraded to B from B+ on 9/22/2014 due to a decline in the valuation index and dividend index.
AbbVie Inc. (ABBV) was downgraded to B from B+ on 9/22/2014 due to a decline in the valuation index and dividend index.
B
Buy
8/8/2014Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 8/8/2014 due to a large increase in the growth index, efficiency index and valuation index. Operating cash flow increased 175.16% from $624M to $1.72B, EBIT increased 21.1% from $1.35B to $1.64B, and net income increased 12.04% from $980M to $1.1B.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 8/8/2014 due to a large increase in the growth index, efficiency index and valuation index. Operating cash flow increased 175.16% from $624M to $1.72B, EBIT increased 21.1% from $1.35B to $1.64B, and net income increased 12.04% from $980M to $1.1B.
B
Buy
7/1/2014Upgraded
AbbVie Inc. (ABBV) was upgraded to B from D on 7/1/2014 due to an increase in the volatility index and total return index.
AbbVie Inc. (ABBV) was upgraded to B from D on 7/1/2014 due to an increase in the volatility index and total return index.
D
Sell
6/30/2014Downgrade
AbbVie Inc. (ABBV) was downgraded to D from B on 6/30/2014 due to a noticeable decline in the growth index, valuation index and dividend index. Operating cash flow declined 49.88% from $1.25B to $624M, EBIT declined 21.18% from $1.71B to $1.35B, and earnings per share declined from $0.6853 to $0.61.
AbbVie Inc. (ABBV) was downgraded to D from B on 6/30/2014 due to a noticeable decline in the growth index, valuation index and dividend index. Operating cash flow declined 49.88% from $1.25B to $624M, EBIT declined 21.18% from $1.71B to $1.35B, and earnings per share declined from $0.6853 to $0.61.
B
Buy
5/1/2014Downgrade
AbbVie Inc. (ABBV) was downgraded to B from B+ on 5/1/2014 due to a decline in the valuation index, total return index and dividend index.
AbbVie Inc. (ABBV) was downgraded to B from B+ on 5/1/2014 due to a decline in the valuation index, total return index and dividend index.
B
Buy
4/16/2014Upgraded
AbbVie Inc. (ABBV) was upgraded to B+ from B on 4/16/2014 due to a large increase in the volatility index, total return index and valuation index.
AbbVie Inc. (ABBV) was upgraded to B+ from B on 4/16/2014 due to a large increase in the volatility index, total return index and valuation index.
B
Buy
2/28/2014Upgraded
AbbVie Inc. (ABBV) was upgraded to B from D on 2/28/2014 due to a large increase in solvency, efficiency and growth. Debt to equity declined from 4.24 to 3.28, net income increased 17.01% from $964M to $1.13B, and earnings per share increased from $0.6 to $0.6853.
AbbVie Inc. (ABBV) was upgraded to B from D on 2/28/2014 due to a large increase in solvency, efficiency and growth. Debt to equity declined from 4.24 to 3.28, net income increased 17.01% from $964M to $1.13B, and earnings per share increased from $0.6 to $0.6853.
NYSE
04/24/2024 10:50AM Eastern
Quotes delayed
